While at the time of this article, CLBS ATR is sitting at 0.24, with the beta value at 1.58. The warrants have an exercise price equal to $2.0625 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock. H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering.BASKING RIDGE, N.J., May 14, 2020 -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the.Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Below are the latest news stories about Caladrius Biosciences Inc that investors may wish to consider to help them evaluate CLBS as an investment opportunity. Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). This stock’s volatility for the past week remained at 10.15%, while it … At the most recent market close, shares of Caladrius Biosciences Inc. [NASDAQ:CLBS] were valued at $2.47.If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 4.49 and the whole liability to whole assets at 3.60. On January 08, 2016, H.C. Wainwright Downgrade a Neutral rating. Caladrius Biosciences Inc. News: Why CLBS Stock Is Trending Lower Today Now if looking for a valuation of this stock’s amount to book ratio is 1.27. According to news published on The most recent analyst activity for Caladrius Biosciences Inc. [NASDAQ:CLBS] stock was on November 20, 2018, when it was Resumed with a Buy rating from H.C. Wainwright, which also raised its 12-month price target on the stock to $18.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.21. On January 07, 2016, Maxim Group Downgrade a Hold rating.
Please disable your ad-blocker and refresh. The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions. CLBS has fallen -$0.06 from the previous closing price of $2.53 on volume of 1.01 million shares.On 2, June 2020, Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase. While at the time of this article, CLBS ATR is sitting at 0.24, with the beta value at 1.58. If you have an ad-blocker enabled you may be blocked from proceeding. This stock’s volatility for the past week remained at 10.15%, while it was 10.68% for the past 30-day period. Find the latest news headlines from Caladrius Biosciences, Inc. Common Stock (CLBS) at Nasdaq.com. On April 29, 2016, H.C. Wainwright Upgrade a Buy rating and increased its price target to $1.25.